Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

AI Briefing

• – Zymeworks Inc. reports Q4 2025 earnings, discussing revenue growth and partnerships.
• – The company highlights advancements in its therapeutics pipeline, including the successful completion of a Phase 1 clinical trial.
• – Outlook for 2026 remains positive, with expected continued progress in the development of its innovative cancer therapies.